MBX Biosciences raises $163.2 million in US IPO

MBX Biosciences has successfully raised $163.2 million in its U.S. IPO by pricing shares at $16 each, giving the company a valuation of $482.5 million. The biotechnology firm is working on treatments for chronic hypoparathyroidism and obesity, with its lead experimental candidate aimed at addressing low parathyroid hormone levels and another therapy in preclinical development for weight loss.